Published in Proc Soc Exp Biol Med on July 01, 1974
Characteristics of noncultivable adenoviruses associated with diarrhea in infants: a new subgroup of human adenoviruses. J Clin Microbiol (1979) 1.56
Antibodies in urine of chimpanzees with chronic adenoviral viruria. Infect Immun (1978) 0.79
Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 5.19
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53
Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med (1989) 3.16
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Coronavirus infection in acute lower respiratory tract disease of infants. J Infect Dis (1974) 2.55
Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med (1974) 2.46
Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations--Huntington, WVa, and Stockholm, Sweden. Chest (1993) 2.17
Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17
United we stand. Ann Intern Med (1993) 2.16
Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol (1991) 2.14
The role of viruses, mycoplasmas and bacteria in acute pneumonia in civilian adults. Am J Epidemiol (1967) 2.11
Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol (1987) 2.06
Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect Immun (1978) 1.96
Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis (1976) 1.95
Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis (1995) 1.83
Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis (1993) 1.78
Experimental respiratory syncytial virus infection of four species of primates. J Med Virol (1977) 1.74
Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B. J Gen Virol (1987) 1.73
Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics (2001) 1.70
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis (1993) 1.62
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J Infect Dis (1988) 1.58
Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus. Proc Natl Acad Sci U S A (1987) 1.55
Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res (1992) 1.51
Palmitoylation of the influenza A virus M2 protein. Virology (1990) 1.51
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Structural differences between subtype A and B strains of respiratory syncytial virus. J Gen Virol (1986) 1.45
Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother (1991) 1.43
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med (1991) 1.43
Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: I. Viral shedding, immunologic response, and associated illness. J Med Virol (1978) 1.42
Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA (1995) 1.40
Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr (1992) 1.38
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine (2000) 1.38
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun (1994) 1.35
Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens. Antimicrob Agents Chemother (1990) 1.35
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis (1998) 1.33
Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults. J Clin Microbiol (1990) 1.31
Pneumococcal infections. JAMA (1981) 1.30
Experimental respiratory syncytial virus pneumonia in cebus monkeys. J Med Virol (1978) 1.30
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis (2000) 1.29
Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults. J Infect Dis (1977) 1.29
Diplococcus pneumoniae infections in children with sickle cell anemia. Am J Dis Child (1972) 1.29
Cold-recombinant influenza A/California/10/78 (H1N1) virus vaccine (CR-37) in seronegative children: infectivity and efficacy against investigational challenge. J Infect Dis (1984) 1.28
Respiratory syncytial virus: heterogeneity of subgroup B strains. J Gen Virol (1988) 1.27
Viral antibodies among the Turkana people of Northern Kenya. Trop Geogr Med (1972) 1.27
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Nosocomial influenza B virus infection in the elderly. Ann Intern Med (1982) 1.25
Simultaneous nosocomial and community outbreak of epidemic keratoconjunctivitis with types 8 and 19 adenovirus. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol (1977) 1.25
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay. J Clin Microbiol (1994) 1.25
Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol (1991) 1.24
Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis (2000) 1.23
Serological diagnosis of influenza B virus infection: comparison of an enzyme-linked immunosorbent assay and the hemagglutination inhibition test. J Clin Microbiol (1982) 1.23
Pneumococcal disease in a medium-sized community in the United States. JAMA (1982) 1.22
Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus. J Virol (1977) 1.21
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis (1996) 1.21
Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J Gen Virol (1994) 1.20
Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol (1982) 1.19
Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis (1996) 1.19
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J Infect Dis (1998) 1.18
Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis (2000) 1.17
A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination. J Lab Clin Med (1999) 1.15
Antigenic and genetic diversity among the attachment proteins of group A respiratory syncytial viruses that have caused repeat infections in children. J Infect Dis (1998) 1.14
Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. J Infect Dis (1986) 1.12
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses (1998) 1.12
Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". J Infect Dis (1994) 1.09
Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol (1995) 1.08
Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am J Epidemiol (1973) 1.05
Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates: II. Genetic analysis of virus recovered during infection. J Med Virol (1978) 1.05
Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3. J Med Virol (1986) 1.05
Live attenuated influenza A virus vaccines in children: results of a field trial. J Infect Dis (1984) 1.03
Viruses, Mycoplasma pneumoniae and bacteria associated with lower respiratory tract disease among infants. Am J Epidemiol (1970) 1.03
Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis (1993) 1.01
A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988. J Clin Microbiol (1991) 1.01
Acquisition of parainfluenza 3 virus infection by hospitalized children. I. Frequencies, rates, and temporal data. J Infect Dis (1973) 1.00
Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med (1994) 1.00
Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis (1978) 0.99
A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop. J Virol (1990) 0.99
Epidemiology of severe respiratory syncytial virus infections in Huntington, West Virginia. W V Med J (1981) 0.98
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1999) 0.98
Shedding of infectious virus and virus antigen during acute infection with respiratory syncytial virus. J Med Virol (1992) 0.98
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J (2001) 0.98
The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis (2012) 0.97
Superiority of tissue-culture-grown antigens over egg-grown antigens for serologic diagnosis of influenza B virus infections. J Med Virol (1986) 0.97
The sudden infant death syndrome and epidemic viral disease. Am J Epidemiol (1975) 0.97
Impact of viral respiratory diseases on infants and young children in a rural and urban area of southern West Virginia. Am J Epidemiol (1983) 0.97
Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. J Clin Microbiol (1986) 0.97
Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production. J Infect Dis (2001) 0.97
Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med (1983) 0.97
From the National Institutes of Health: report of a workshop on respiratory syncytial virus and parainfluenza viruses. J Infect Dis (1978) 0.96
Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. Scand J Infect Dis (1991) 0.96
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (1997) 0.96
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network. Vaccine (1995) 0.95